Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Davies, Stella M  [Clear All Filters]
2016
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, et al. A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Nelson AS, Marsh RA, Myers KC, Davies SM, Jodele S, O'Brien TA, Mehta PA. A reduced intensity conditioning regimen for patients with Dyskeratosis Congenita undergoing hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2016.
Teusink-Cross A, Davies SM, Danziger-Isakov L, El-Bietar J, Grimley MS. Restrictive palivizumab use does not lead to increased morbidity and mortality in pediatric hematopoietic stem cell transplant patients. Biol Blood Marrow Transplant. 2016.
Khandelwal P, Bleesing JJ, Davies SM, Marsh RA. A Single Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced Intensity Conditioning to Myeloablative Busulfan, Cyclophosphamide, and Anti-Thymocyte Globulin for Chronic Granulomatous Disease. Biol Blood Marrow Transplant. 2016.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM. Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.
2015
Wallace G, Jodele S, Howell J, Myers KC, Teusink A, Zhao X, Setchell K, Holtzapfel C, Lane A, Taggart C, et al. Vitamin D Deficiency and Survival in Children after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2015.

Pages